Clinical Trial

Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects

Study acronym: CBT101
Completed Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-25.
Status change: Recruiting → Completed 2026-03-26
Trial Details
NCT Number NCT07050316
Lead Sponsor Ceres Brain Therapeutics
Collaborators: Eurofins Optimed
Conditions Neurologic Diseases, General
Enrollment 48 participants
Start Date 2025-03-14
Primary Completion 2025-09-26 (estimated)
Study Completion 2025-09-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-27